MiR-760 inhibits the progression of non-small cell lung cancer through blocking ROS1/Ras/Raf/MEK/ERK pathway.

The purpose of this study was to investigate the role of miR-760 in non-small cell lung cancer (NSCLC), as well as relevant molecular mechanisms. Expression patterns of miR-760 in NSCLC tissues and cells were detected using quantitative real-time polymerase chain reaction (qRT-PCR) method. Cell transfection was performed using Lipofectamine® 2000. MTT and transwell assays were used to detect cell proliferation and migration in vitro, respectively. Potential target of miR-760 in NSCLC was predicted via bioinformatics analysis, and confirmed by luciferase reporter assay. Protein analysis was performed through western blot. The levels of miR-760 were down-regulated in NSCLC tissues and cells, compared with non-cancerous specimens (p<0.05 for all). Enforced expression of miR-760 inhibited cell proliferation, migration and invasion. Furthermore, the over-expression of miR-760 could suppress the activity of ROS1/Ras/Raf/MEK/ERK pathway. ROS1 might be a target gene of miR-760 in NSCLC. ROS1 could reverse anti-tumor effect of miR-760 in the progression of NSCLC. MiR-760 may act as a tumor suppressor against NSCLC. MiR-760 could block ROS1/Ras/Raf/MEK/ERK pathway through inhibiting ROS1 expression, thus repressing the progression of NSCLC. Copyright 2020 The Author(s).